Tonix Pharmaceuticals Holding Corp. has released preliminary financial results for the quarter ended June 30, 2025. The company reported a net revenue of $2.0 million from the sale of its marketed products, slightly down from $2.2 million in the same period in 2024. The net operating loss significantly decreased to $26.3 million for the quarter, compared to $78.8 million in the previous year. The company's net cash used in operating activities increased to $16.3 million, up from $9.9 million in the same quarter the previous year. Additionally, capital expenditures for the quarter were approximately $1.1 million, compared to $0 in the same period in 2024. Tonix Pharmaceuticals ended the quarter with approximately $125.3 million in cash and cash equivalents. The company expects that its cash resources, along with the $50.6 million raised from equity offerings in the third quarter of 2025, will meet its planned operating and capital expenditure requirements into the third quarter of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.